the company is providing full-year 2023 financial guidance as follows: EXPAREL net product sales of $570 million to $580 million; ZILRETTA net product sales of $115 million to $125 million; iovera degrees net product sales of $17 million to $20 million; Non-GAAP Gross margin of 76% to 78%; Non-GAAP R&D expense of $70 million to $80 million; Non-GAAP SG&A expense of $220 million to $230 million; and Stock-based compensation of $51 million to $54 million.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PCRX:
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
- Pacira, LPGA partner to raise awareness of non-opioid pain management solutions
- Pacira to Report 2022 Financial Results on Tuesday February 28, 2023
- Pacira price target lowered to $69 from $76 at H.C. Wainwright
- Pacira assumed with an Outperform at Wedbush
